Used for the treatment of prostate cancer and neuroendocrine tumors.
Radiopharmaceutical Precursor Solution containing Lutetium (177Lu) Chloride and hydrochloric acid and water as excipients.
Radiopharmaceutical precursor. Not directly administered to the patient. This medicinal product is used only for labeling molecules suitable for labeling with Lu-177 radionuclide.
Guaranteed calibrated delivery every day of the week
The most important benefits:
- Continuous supply of Lu-177 guaranteed due to cooperation with various nuclear reactors
- Availability- on a weekly basis all year round
- V Shaped for minimum material loss
- Each lot is tested for labeling efficiency
|Radionuclide||177LU Lutetium Chloride Solution|
|Manufacturing Date||Every Friday|
|Packaging||3 ml Type V, V Bottle, Glass Vial
10 ml Typ I, Flat Bottom Vial, Glass Vial
|Half -life||6,648 days|
|Chemical form||LuCl3 in 0.05 HCI|
|Radiochemical Concentration||37 GBq / mL|
|Radionuclide Purity||≥ 99.9% Lutetium-177
≤ 0.07% Lutetium-177m
≤ 0.01% Other Impurities
|Chemical Purity||Cu ≤ 1.0 μg/GBq
Fe ≤ 0.5 μg/GBq
Pb ≤ 0.5 μg/GBq
Zn ≤ 1.0 μg/GBq
|Shelf life||8 days after production|